This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Insilico Medicine’s partnership with Hengtai Biotech to co-develop an AI-discovered NLRP3 inhibitor for CNS disorders and Ellipses Pharma’s licensing of a first-in-class B7H3 ADC from Innolake Biopharm. IPO filings by Dizal Pharmaceutical, Biosun Pharma, and Fosun Adgenvax highlight the growing activity in oncology, autoimmune diseases, and vaccine innovations. Licensing deals, such as AstraZeneca acquiring full rights to AbelZeta’s GPC3 CAR-T therapy, showcase continued interest in advanced cell therapies. Clinical breakthroughs, including approvals for AbbVie’s risankizumab in ulcerative colitis and AstraZeneca’s durvalumab in endometrial cancer, reflect significant advancements in addressing unmet medical needs.
